We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Foresee Pharmaceuticals

News List

Foresee Pharmaceuticals Announces Completion of US$47 Million Financing prnasia
December 25, 2020
Foresee pharmaceuticals announces that it has successfully completed an underwritten public offering of 15,000,000 shares of its common stock to the public at a price of NT$88 per share.
Foresee Pharmaceuticals Announces NDA for CAMCEVI(TM) 42MG Accepted for Review by the FDA prnasia
October 10, 2020
Foresee Pharmaceuticals Co., Ltd. announced that the 505(b)(2) New Drug Application (NDA) for FP-001 LMIS 50mg, or CAMCEVI™ 42MG, a ready-to-use 6-month depot formulation of leuprolide mesylate, has been accepted for review by the U.S. Food and Drug ...